Korea South
ORGANOIDSCIENCES is a Korean biotech startup founded in 2018 with a focus on the commercialization of the world's first organoid treatment. The company's innovative approach lies in utilizing organoid-based drug screening and regenerative medicines. With its recent $17.69M Series B investment on 13 January 2022, ORGANOIDSCIENCES has attracted funding from notable investors including Company K Partners, LB Investment, Aju IB Investment, MINT Venture Partners, Atinum Partners, and E&Venture Partners.
The startup operates within the Biopharma and Biotechnology industries, positioning itself as a pioneering force in the field. Its strong emphasis on leveraging organoid technology for medical advancements underscores its commitment to addressing critical healthcare challenges. The company's slogan, "Commercialization of the world's first organoid treatment", encapsulates its mission to bring groundbreaking therapies to the market.
ORGANOIDSCIENCES's latest investment round not only signifies a significant infusion of capital but also symbolizes a vote of confidence from seasoned investors. The company's strategic vision, backed by substantial funding, positions it for further growth and development within the biotech landscape.
